Back to today’s briefing

Story perspectives

FDA Chief Faces Backlash Over Moderna Vaccine Rejection

2/14/2026

38 4 Full Breakdown

Summary

Story summary

Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER), is criticized for overruling agency scientists and rejecting Moderna's mRNA-based influenza vaccine.
Internal complaints allege harassment and retaliation by Prasad.
A team of FDA scientists was ready to review the submission.
Public health experts call for transparency as Moderna's application remains in limbo.

History

Historical Context

The COVID-19 pandemic prompted unprecedented vaccine development, leading to the FDA's emergency authorization of the Pfizer-BioNTech mRNA vaccine on December 11, 2020, after trials with over 43,000 participants showed 95% efficacy. This innovation marked a significant shift in vaccine technology, echoing historical tensions over FDA transparency and scientific integrity, crucial for public trust in health initiatives.

1 of 2

Story summary

Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER), is criticized for overruling agency scientists and rejecting Moderna's mRNA-based influenza vaccine.
Internal complaints allege harassment and retaliation by Prasad.
A team of FDA scientists was ready to review the submission.
Public health experts call for transparency as Moderna's application remains in limbo.

1 / 2